IJARSCT
ISSN (Online) 2581-9429
International Journal of Advanced Research in Science, Communication and Technology (IJARSCT)
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
Impact Factor: 7.53
Volume 4, Issue 5, November 2024

A Comprehensive Review of Renal Failure: Causes, Symptoms, and Management

Sable Mahavir Ashok, Prof. Priyanka V Jadhav and Dr Sanjay Ingle
Dharmaraj Shaishanik Pratisthan College of Pharmacy, Walki, Ahaemadnagar, India

Abstract: *Renal failure, also known as kidney failure, is a significant global health concern characterized by the inability of the kidneys to adequately filter waste products from the blood. This review provides a detailed examination of the causes, symptoms, and management strategies associated with renal failure. The condition is broadly classified into acute renal failure (ARF) and chronic renal failure (CRF), each with distinct etiologies and clinical manifestations. Common causes include diabetes mellitus, hypertension, glomerulonephritis, and exposure to nephrotoxic substances. Symptoms often involve fatigue, fluid retention, electrolyte imbalances, and decreased urine output. Early diagnosis and intervention are crucial in preventing progression to end-stage renal disease (ESRD). Management approaches vary depending on the stage and type of renal failure but typically include lifestyle modifications, pharmacological treatments, dialysis, and kidney transplantation in severe cases. This review emphasizes the importance of preventive measures, including proper management of underlying conditions and regular monitoring of kidney function, to mitigate the risk of renal failure. Recent advancements in treatment options, as well as emerging therapies, are also discussed to provide a comprehensive overview of the current and future landscape of renal failure management.*

Keywords: Normal saline, history, 0.9% sodium chloride solution, types of saline, types of normal saline

I. INTRODUCTION

The 17th century marked a turning point in the understanding of renal physiology. English physician William Harvey's discovery of blood circulation in 1628 was pivotal for understanding how blood flow related to kidney filtration (1). Richard Lower (1631–1691) demonstrated that the kidneys were involved in filtering blood to produce urine, establishing a clearer connection between kidney function and systemic health (2). By the 19th century, clinicians began recognizing specific renal pathologies. Richard Bright (1789–1858), an English physician, is often credited as the founder of nephrology . In the 1820s, Bright linked kidney disease to the clinical symptoms of edema (swelling) and high blood pressure, identifying what would later be called "Bright's disease" (chronic nephritis) . His observations were groundbreaking in correlating proteinuria (protein in the urine) with kidney dysfunction, foreshadowing modern methods of diagnosing kidney failure through laboratory markers (3). In 1839, Thomas Addison further expanded on the study of kidney diseases, recognizing various forms of kidney inflammation and damage (4). This era laid the foundation for identifying causes of renal failure, though treatments were still limited (5).

Renal failure, commonly referred to as kidney failure, is a serious medical condition characterized by the kidneys' inability to adequately filter waste products and excess fluids from the blood, resulting in imbalanced electrolytes and the accumulation of toxins (6). This condition represents a final common pathway for many kidney-related diseases and systemic conditions, impacting millions of people worldwide (7). Renal failure can be classified into two broad categories: acute kidney injury (AKI) and chronic kidney disease (CKD) (8). Both forms carry significant morbidity and mortality risks, particularly as they often progress silently until the later stages (9).

Importance of Renal Function

The kidneys are essential organs responsible for maintaining homeostasis in the body. They regulate fluid balance, electrolyte levels, and acid-base equilibrium, while also removing metabolic waste products like urea and creatinine (10). Additionally, the kidneys play a key role in blood pressure regulation, red blood cell production through the secretion of erythropoietin, and the activation of vitamin D, which is crucial for bone health (11). Given the wide-

IJARSCT
ISSN (Online) 2581-9429
International Journal of Advanced Research in Science, Communication and Technology (IJARSCT)
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
Impact Factor: 7.53
Volume 4, Issue 5, November 2024

ranging functions of the kidneys, any decline in their ability to perform these tasks can have profound systemic effects. In renal failure, the loss of these critical functions can lead to complications such as hyperkalemia (elevated potassium levels), metabolic acidosis, hypertension, anemia, and osteodystrophy (12). These complications, if left untreated, can lead to life-threatening consequences, including cardiovascular events, neurological impairments, and multi-organ failure (13). Therefore, understanding the causes, symptoms, and management strategies for renal failure is crucial for improving patient outcomes and reducing the disease burden (14).

Global Burden and Impact

Renal failure is a growing global health concern, with increasing prevalence driven by the rise in risk factors such as diabetes, hypertension, and obesity (15). According to the World Health Organization (WHO), chronic kidney disease (CKD) is now recognized as a significant cause of death worldwide, particularly in low- and middle-income countries where access to treatment options such as dialysis and kidney transplantation is limited (16). In 2017, the Global Burden of Disease Study ranked CKD as the 12th leading cause of death, with projections indicating that it will become the 5th leading cause by 2040 (17).

Acute kidney injury (AKI), on the other hand, is a common complication in hospitalized patients, particularly those in intensive care units (ICUs) (18). AKI can result from multiple causes, including sepsis, hypovolemia (low blood volume), nephrotoxic medications, and trauma (19).

While AKI is potentially reversible if diagnosed and treated promptly, it significantly increases the risk of developing CKD later in life, thus linking acute and chronic forms of renal failure in a continuum (20).

Causes of Renal Failure: A Detailed Overview

Renal failure, whether acute or chronic, can arise from a wide variety of causes that affect the kidneys' ability to filter waste and regulate essential bodily functions. This section of the review will explore the underlying etiologies of both acute kidney injury (AKI) and chronic kidney disease (CKD), detailing the pathophysiological mechanisms and the various factors contributing to kidney dysfunction. The causes are often multifactorial, involving systemic diseases, environmental exposures, genetic predispositions, and direct kidney injury. Understanding these causes is critical for preventing progression, optimizing treatment, and managing patient outcomes.

1. Causes of Acute Kidney Injury (AKI)

Acute Kidney Injury (AKI) is characterized by a rapid decline in kidney function over hours to days. The causes of AKI are typically divided into prerenal, intrinsic (intrarenal), and postrenal categories based on where the dysfunction occurs within the renal system.(21)

A. Prerenal Causes

Prerenal AKI occurs due to reduced blood flow to the kidneys, impairing their ability to filter waste. While the kidneys themselves remain structurally intact, prolonged ischemia can lead to intrinsic damage if not corrected.

• Hypovolemia: Dehydration, excessive blood loss (hemorrhage), or fluid loss from severe vomiting, diarrhea, or burns can significantly reduce the blood volume, leading to decreased renal perfusion.

• Heart Failure and Cardiovascular Shock: Conditions that impair cardiac output, such as congestive heart failure, myocardial infarction, or cardiogenic shock, reduce blood flow to the kidneys.

• Sepsis: Severe infections can cause systemic vasodilation and hypotension, reducing renal blood flow.

• Renal Artery Stenosis: Narrowing of the renal arteries due to atherosclerosis or fibromuscular dysplasia decreases the amount of blood reaching the kidneys, leading to prerenal AKI.(22)

B. Intrinsic Causes

Intrinsic AKI results from direct damage to the kidney tissue. This category encompasses diseases affecting the glomeruli, tubules, or interstitium of the kidney.

• Acute Tubular Necrosis (ATN): The most common cause of intrinsic AKI, ATN results from prolonged ischemia (as seen in prerenal AKI) or exposure to nephrotoxic agents. Common nephrotoxins include:

IJARSCT
ISSN (Online) 2581-9429
International Journal of Advanced Research in Science, Communication and Technology (IJARSCT)
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
Impact Factor: 7.53
Volume 4, Issue 5, November 2024

o Medications: Aminoglycosides (antibiotics), nonsteroidal anti-inflammatory drugs (NSAIDs), and contrast agents used in imaging procedures.
o Rhabdomyolysis: Muscle breakdown releases myoglobin, which can obstruct renal tubules and cause toxic injury.
o Hemolysis: The breakdown of red blood cells releases free hemoglobin, which is nephrotoxic in high amounts.
• Acute Glomerulonephritis: Inflammation of the glomeruli, the filtering units of the kidney, can be caused by autoimmune diseases such as lupus, infections like streptococcal throat infections (post-infectious glomerulonephritis), or vasculitis.
• Acute Interstitial Nephritis (AIN): Inflammatory injury to the kidney interstitium, typically triggered by allergic reactions to drugs (e.g., antibiotics, NSAIDs) or infections. AIN is a relatively rare cause of AKI but can be reversible if detected early.(23)

C. Postrenal Causes

Postrenal AKI occurs due to obstruction of urine flow, leading to backpressure on the kidneys and impaired filtration. This is often reversible if the obstruction is relieved quickly.
• Urinary Tract Obstruction: Common causes include benign prostatic hyperplasia (BPH), kidney stones, or tumors compressing the ureters or bladder.
• Urethral Stricture: Narrowing of the urethra can obstruct urine flow, leading to postrenal AKI.
• Neurogenic Bladder: Impaired bladder function due to nerve damage, often seen in patients with spinal cord injuries, can lead to postrenal AKI.(24)

2. Causes of Chronic Kidney Disease (CKD)

Chronic Kidney Disease (CKD) is defined as a gradual loss of kidney function over months to years. Unlike AKI, CKD is typically irreversible and progresses over time, leading to end-stage renal disease (ESRD) if untreated. CKD is often asymptomatic in its early stages, which makes understanding the underlying causes critical for early intervention and prevention.(25)

A. Systemic Diseases

Diabetes Mellitus is the leading cause of CKD worldwide. Chronic hyperglycemia leads to damage of the kidney's filtering units (glomeruli), a condition known as diabetic nephropathy. This manifests as proteinuria (albumin leakage into the urine) and progressive kidney function decline.
• Mechanism: High blood sugar damages the blood vessels in the kidneys, leading to thickening of the glomerular basement membrane and increased permeability. Over time, this reduces the kidney's filtration capacity.
Hypertension (high blood pressure) is another major cause of CKD. Chronically elevated blood pressure causes damage to the renal vasculature, leading to hypertensive nephrosclerosis. This results in scarring and loss of functional nephrons.
• Mechanism: The increased pressure in blood vessels damages the small arteries within the kidneys, leading to ischemia and sclerosis of kidney tissue.
Autoimmune Diseases: Conditions such as systemic lupus erythematosus (SLE) and IgA nephropathy (Berger's disease) can cause CKD through chronic inflammation of the kidneys. These autoimmune disorders lead to glomerulonephritis, where the body's immune system attacks kidney tissues, resulting in long-term damage.(26)

B. Genetic and Hereditary Causes

Polycystic Kidney Disease (PKD) is a genetic disorder that causes the development of multiple fluid-filled cysts in the kidneys. Over time, these cysts enlarge and replace normal kidney tissue, leading to progressive kidney failure.
• Autosomal Dominant PKD (ADPKD): This is the most common form and usually manifests in adulthood, though the disease progression can be slow, with symptoms often appearing in middle age.
• Autosomal Recessive PKD (ARPKD): A rarer form that typically presents in infancy or childhood and progresses rapidly.

IJARSCT
ISSN (Online) 2581-9429
International Journal of Advanced Research in Science, Communication and Technology (IJARSCT)
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
Impact Factor: 7.53
Volume 4, Issue 5, November 2024

Alport Syndrome: A genetic disorder characterized by the development of abnormal collagen in the kidney's glomeruli. This leads to progressive loss of kidney function, often accompanied by hearing loss and eye abnormalities.(27)

C. Environmental and Lifestyle Factors

Nephrotoxic Drugs: Chronic use of certain medications, including nonsteroidal anti- inflammatory drugs (NSAIDs), certain antibiotics (aminoglycosides), and lithium (used for mood disorders), can contribute to the development of CKD by causing cumulative damage to the kidneys.

Toxins and Heavy Metals: Chronic exposure to toxins such as lead, mercury, or certain industrial chemicals can cause tubulointerstitial nephritis, leading to scarring of the kidneys over time.

Chronic Infections: Long-standing infections, such as chronic pyelonephritis (kidney infections), or recurrent episodes of acute infections can lead to progressive renal damage and CKD.

D. Obstructive Causes

Chronic urinary tract obstructions, such as those caused by benign prostatic hyperplasia (BPH), recurrent kidney stones, or ureteral strictures, can cause obstructive uropathy, leading to long-term damage to kidney function.

E. Glomerular Diseases

Glomerulonephritis: Chronic inflammation of the glomeruli can lead to progressive damage and CKD. Common types of chronic glomerulonephritis include focal segmental glomerulosclerosis (FSGS), membranous nephropathy, and minimal change disease.

F. Vascular Causes

Renal Artery Stenosis: Atherosclerosis or fibromuscular dysplasia causing narrowing of the renal arteries can lead to ischemic nephropathy, where reduced blood flow causes progressive kidney damage over time.

Vasculitis: Inflammatory conditions such as granulomatosis with polyangiitis (formerly Wegener's granulomatosis) can damage the small blood vessels in the kidneys, leading to CKD (28)

4 Symptoms



IJARSCT
ISSN (Online) 2581-9429
International Journal of Advanced Research in Science, Communication and Technology (IJARSCT)
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
Impact Factor: 7.53
Volume 4, Issue 5, November 2024

1. Acute Kidney Injury (AKI) is characterized by a rapid decline in kidney function over hours to days, often presenting with sudden onset of symptoms. In some cases, AKI may be asymptomatic and diagnosed only through laboratory tests. The clinical presentation of AKI depends on the underlying cause and severity of the condition.

A. Oliguria or Anuria

• Oliguria (urine output <400 mL/day) or anuria (absence of urine) is a hallmark symptom of AKI. Oliguria occurs due to the kidneys' inability to filter blood and produce urine (29).
• In prerenal AKI, oliguria results from decreased renal blood flow, whereas in postrenal AKI, it results from urinary tract obstruction(30).
• Intrinsic AKI, such as acute tubular necrosis (ATN) or glomerulonephritis, commonly presents with oliguria (31).

B. Edema

• Fluid retention, due to the kidney's inability to excrete excess water, leads to edema. Swelling is often seen in the legs, ankles, and face(32).
• In severe cases, pulmonary edema may occur, leading to shortness of breath and respiratory distress (33).

C. Electrolyte Imbalances

• Hyperkalemia (high potassium levels) is a dangerous complication of AKI, causing symptoms like muscle weakness and arrhythmias(34).
• Hyponatremia (low sodium levels) may cause confusion, headaches, and seizures(35).
• Hypocalcemia and hyperphosphatemia can lead to muscle cramps and bone pain(36).

D. Metabolic Acidosis

• In AKI, the kidneys lose the ability to excrete hydrogen ions and reabsorb bicarbonate, leading to metabolic acidosis. This condition can manifest as rapid breathing (Kussmaul respirations), fatigue, and confusion(37).

E. Uremia

• Uremia, the accumulation of waste products in the blood, is a key feature of severe AKI, causing symptoms like nausea, vomiting, and fatigue (38).
• Uremic toxins can also cause pericarditis, resulting in chest pain and dyspnea (39).

F. Hypertension

• In prerenal and intrinsic AKI, impaired kidney function can lead to hypertension, further damaging the kidneys(40).

G. Nonspecific Symptoms

• Patients with AKI may experience general symptoms such as fatigue, weakness, and loss of appetite due to toxin buildup (41).
• Infections, especially urinary tract infections (UTIs), are common in postrenal AKI due to urinary obstruction (42).

2. Symptoms of Chronic Kidney Disease (CKD)

CKD progresses slowly over months or years, and its symptoms may be subtle in the early stages. By the time symptoms appear, CKD may have progressed significantly(43).

A. Early-Stage Symptoms

• Fatigue and weakness are common early signs due to anemia and toxin buildup (44).
• Loss of appetite, nausea, and unexplained weight loss are often due to uremia (45).

IJARSCT
ISSN (Online) 2581-9429
International Journal of Advanced Research in Science, Communication and Technology (IJARSCT)
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
Impact Factor: 7.53
Volume 4, Issue 5, November 2024

• Nocturia (frequent nighttime urination) may occur as the kidneys lose their ability to concentrate urine.

B. Edema and Fluid Retention

• As CKD worsens, sodium and fluid retention lead to edema, especially in the legs, ankles, and face (46).
• Pulmonary edema and shortness of breath may occur as CKD progresses(47).

C. Electrolyte Imbalances

• Hyperkalemia is common in advanced CKD, causing muscle weakness and irregular heartbeats(48).
• Hypocalcemia and hyperphosphatemia may lead to bone pain and muscle cramps due to impaired phosphate excretion (49).
• Metabolic acidosis can cause fatigue, headaches, and breathing difficulties (50).

D. Hypertension

• Hypertension is both a cause and a consequence of CKD. As kidney function declines, blood pressure increases, exacerbating kidney damage (51).

E. Anemia

• CKD patients often develop anemia due to reduced erythropoietin production, leading to fatigue, pallor, and shortness of breath (52)

F. Uremia

• In advanced CKD, uremic syndrome causes nausea, vomiting, a metallic taste, confusion, and restless legs(53).
• Pruritus (itching) and a foul odor to the breath are common due to toxin buildup (54).

G. Cardiovascular Symptoms

• CKD is closely linked with cardiovascular disease. Symptoms include chest pain, palpitations, and shortness of breath (55).

H. Bone and Mineral Disorders

• CKD causes renal osteodystrophy, leading to bone pain, fractures, and muscle cramps (56).

I. Skin and Nail Changes

• CKD patients often experience skin changes like pallor, bruising, and a yellowish hue. Nail changes, such as half-and-half nails, are also common (57).

J. Sexual Dysfunction

• CKD may cause sexual dysfunction due to hormonal imbalances, fatigue, and emotional stress(58).

5 Management

The management of renal failure, whether acute kidney injury (AKI) or chronic kidney disease (CKD), aims to halt or slow disease progression, alleviate symptoms, and prevent complications (59,60). The treatment approach varies based on the type and stage of renal failure, the underlying cause, and the presence of comorbid conditions (61). Successful management relies on early detection, appropriate interventions, and a multidisciplinary approach involving nephrologists, dietitians, pharmacists, and other healthcare professionals (62). This section of the review outlines the comprehensive strategies for managing both AKI and CKD, detailing the medical, lifestyle, and dialysis-based interventions essential for maintaining kidney function and enhancing patient outcomes (60,63).

IJARSCT
ISSN (Online) 2581-9429
International Journal of Advanced Research in Science, Communication and Technology (IJARSCT)
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
Impact Factor: 7.53
Volume 4, Issue 5, November 2024



1. Management of Acute Kidney Injury (AKI)

Acute Kidney Injury (AKI) is a medical emergency that requires prompt recognition and intervention to prevent permanent kidney damage and systemic complications (59,64). The goals of AKI management are to identify and treat the underlying cause, restore normal kidney function, and manage complications such as fluid overload, electrolyte imbalances, and uremia (65).

A. Addressing the Underlying Cause

• Prerenal AKI: Treatment focuses on restoring renal perfusion by correcting the cause of hypovolemia or reduced blood flow to the kidneys (66). Common strategies include intravenous fluids, such as isotonic saline or colloid solutions, to restore blood volume in cases of dehydration, blood loss, or sepsis (67). Blood pressure management involves optimizing cardiac output in patients with heart failure or hypotension, often with vasopressors or inotropes .

• Intrinsic AKI: Treatment varies based on the specific cause of kidney injury (68). For acute tubular necrosis (ATN), supportive care is key, as there is no specific therapy (69). Measures include avoiding nephrotoxins and optimizing fluid balance (70). In cases of acute glomerulonephritis, immunosuppressive therapy, such as corticosteroids or cyclophosphamide, is used for immune-mediated causes like lupus or vasculitis (71). Acute interstitial nephritis (AIN) requires the withdrawal of the offending drug (e.g., NSAIDs, antibiotics), and corticosteroids may be used in some cases (72).

• Postrenal AKI: Removing the obstruction is the primary goal, which may involve catheterization or surgical intervention to relieve urinary retention caused by prostatic hypertrophy, stones, or tumors (73). In some cases, stenting or nephrostomy is used to bypass obstructions in the ureters (74).

B. Fluid and Electrolyte Management

Fluid management is critical in AKI as it often involves disturbances in fluid balance (75). Monitoring of fluid intake and output is essential, especially in oliguric AKI, where avoiding fluid overload is crucial to prevent pulmonary edema

IJARSCT
ISSN (Online) 2581-9429
International Journal of Advanced Research in Science, Communication and Technology (IJARSCT)
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
Impact Factor: 7.53
Volume 4, Issue 5, November 2024

(76). In hypovolemic states, fluid resuscitation is required, while diuretics like furosemide may be administered in cases of fluid overload (77). Electrolyte imbalances, such as hyperkalemia, can be managed with calcium gluconate to stabilize the myocardium and insulin with glucose to drive potassium into cells (78). Severe cases may require potassium binders or dialysis (79).

C. Renal Replacement Therapy (RRT) in AKI

Renal replacement therapy (RRT) is indicated in severe AKI when medical management fails, particularly in life-threatening conditions like refractory hyperkalemia, severe metabolic acidosis, volume overload, or uremic symptoms (80). Hemodialysis or continuous renal replacement therapy (CRRT) can support the patient while allowing the kidneys time to recover . Continuous therapies are often preferred in critically ill patients to avoid rapid fluid shifts (81).

2. Management of Chronic Kidney Disease (CKD)

Chronic Kidney Disease (CKD) progresses gradually and often requires long-term management to slow disease progression, prevent complications, and optimize quality of life (82). Early identification of CKD allows timely interventions, delaying the onset of end-stage renal disease (ESRD) and the need for dialysis or transplantation (83).

A. Slowing Progression of CKD

1. Blood Pressure Control: Hypertension is both a cause and consequence of CKD. Tight control of blood pressure (<130/80 mmHg) is crucial to reduce kidney damage (84). Angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin II receptor blockers (ARBs) are first-line treatments in CKD due to their ability to reduce proteinuria and slow CKD progression (85). Other antihypertensives, such as calcium channel blockers or diuretics, may be added based on the patient's needs (86).
2. Glycemic Control in Diabetic CKD: For patients with diabetic nephropathy, achieving optimal blood glucose levels (HbA1c < 7%) is essential to slowing the progression of kidney disease (87). SGLT2 inhibitors like empagliflozin have shown renal protective effects by reducing hyperfiltration and proteinuria (88). GLP-1 receptor agonists like liraglutide also have potential benefits in diabetic kidney disease (89).
3. Proteinuria Reduction: Reducing proteinuria with ACEIs, ARBs, and mineralocorticoid receptor antagonists (MRAs) improves renal outcomes in CKD (90).
4. Managing Dyslipidemia: Statins are recommended in CKD patients to reduce cardiovascular risk, a leading cause of death in CKD (91,92).

B. Management of Complications

1. Anemia Management: Anemia in CKD is managed with erythropoiesis-stimulating agents (ESAs), such as epoetin alfa or darbepoetin, alongside iron supplementation to maintain hemoglobin levels between 10–11.5 g/dL (93). Monitoring is required to avoid excessive hemoglobin increases that can raise cardiovascular risk (94).
2. Mineral and Bone Disorder (CKD-MBD): CKD often disrupts calcium, phosphate, and vitamin D metabolism, leading to bone disease and vascular calcification (95). Phosphate binders like calcium acetate and sevelamer are used to reduce serum phosphate levels (96). Vitamin D analogs and calcimimetics help manage secondary hyperparathyroidism (97).
3. Electrolyte Imbalances: Hyperkalemia is managed with dietary potassium restriction and potassium binders (98). Metabolic acidosis may require sodium bicarbonate supplementation (99).

C. Lifestyle and Dietary Modifications

Dietary modifications, such as protein restriction (0.6–0.8 g/kg/day), help reduce the accumulation of nitrogenous waste in CKD patients . Sodium restriction (<2 g/day) helps control hypertension and fluid retention (100). Monitoring potassium and phosphate intake is critical in managing hyperkalemia and CKD-MBD . Fluid restriction may be necessary in advanced CKD to prevent fluid overload (101). Smoking cessation and regular exercise improve cardiovascular health and overall well-being (102).

IJARSCT
ISSN (Online) 2581-9429
International Journal of Advanced Research in Science, Communication and Technology (IJARSCT)
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
Impact Factor: 7.53
Volume 4, Issue 5, November 2024

D. Renal Replacement Therapy (RRT) in CKD

When CKD progresses to ESRD, RRT becomes necessary, with options including hemodialysis, peritoneal dialysis, and kidney transplantation . Hemodialysis, the most common form, filters blood through an external machine, while peritoneal dialysis uses the patient's peritoneal membrane for blood filtration (103). Kidney transplantation provides the best long-term outcomes, but requires lifelong immunosuppressive therapy to prevent rejection (104).

E. Patient Education and Support

Patient education is vital for managing medication adherence, dietary restrictions, and regular monitoring, which can prevent complications and slow CKD progression (105). Psychosocial support is important for addressing depression and anxiety often seen in patients with CKD or on dialysis (106).

REFERENCES

[1]. Harvey W. Exercitatio Anatomica de Motu Cordis et Sanguinis in Animalibus [On the Motion of the Heart and Blood in Animals]. 1628.
[2]. Lower R. Tractatus de Corde: Item de Motu & Colore Sanguinis et Chyli in Eum Transitu. 1669.
[3]. Bright R. Reports of Medical Cases Selected with a View of Illustrating the Symptoms and Cure of Diseases by a Reference to Morbid Anatomy. London: Longman, Rees, Orme, Brown, and Green; 1827.
[4]. Addison T. On the Constitutional and Local Effects of Disease of the Supra-Renal Capsules. London: Samuel Highley; 1849.
[5]. National Kidney Foundation. Kidney Failure (Renal Failure). Available from: https://www.kidney.org/atoz/content/kidneyfailure
[6]. Levey AS, Coresh J. Chronic kidney disease. Lancet. 2012;379(9811):165-80.
[7]. KDIGO. KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int Suppl. 2013;3(1):1-150.
[8]. Go AS, Chertow GM, Fan D, et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004;351(13):1296-305.
[9]. Brenner BM. Brenner and Rector's The Kidney. 9th ed. Philadelphia: Saunders; 2011.
[10]. National Institutes of Health (NIH). Kidney Functions and Regulation. Available from: https://www.nhlbi.nih.gov/health/kidney-disease/kidney-function
[11]. KDIGO. Clinical Practice Guidelines for Anemia in Chronic Kidney Disease. Kidney Int Suppl. 2012;2(4):279-335.
[12]. Himmelfarb J, Sayegh MH. Chronic Kidney Disease: A Comprehensive Textbook. Philadelphia: Elsevier Saunders; 2010
[13]. Tonelli M, Riella MC. Chronic Kidney Disease: Risks and Outcomes. Nephron. 2013;123(1-2):1-6.
[14]. Jha V, Garcia-Garcia G, Iseki K, et al. Chronic kidney disease: global dimension and perspectives. Lancet. 2013;382(9888):260-72.
[15]. World Health Organization (WHO). Global Health Estimates: Leading causes of death and disability. Geneva: WHO; 2020. Available from: https://www.who.int/data/gho/data/themes/mortality-and-global-health-estimates
[16]. Murray CJL, Aravkin AY, Zheng P, et al. Global Burden of Disease 2017 study: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018;392(10159):1789-858.
[17]. Susantitaphong P, Cruz DN, Cerda J, et al. World incidence of AKI: a meta-analysis. Clin J Am Soc Nephrol. 2013;8(9):1482-93.
[18]. Mehta RL, Cerdá J, Burdmann EA, et al. International Society of Nephrology's 0by25 initiative for acute kidney injury (AKI): from awareness to action. Kidney Int. 2015;87(1):62-74.
[19]. Coca SG, Singanamala S, Parikh CR. Chronic kidney disease after acute kidney injury: a systematic review and meta-analysis. Kidney Int. 2012;81(5):442-
[20]. Lameire N, Bagga A, Cruz D, De Maeseneer J, Endre Z, Kellum JA, et al. Acute kidney injury: an increasing global concern. Lancet. 2013;382(9887):170-9.

IJARSCT
ISSN (Online) 2581-9429
International Journal of Advanced Research in Science, Communication and Technology (IJARSCT)
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
Impact Factor: 7.53
Volume 4, Issue 5, November 2024

[21]. Bellomo R, Kellum JA, Ronco C. Acute kidney injury. Lancet. 2012;380(9843):756-66.
[22]. Makris K, Spanou L. Acute kidney injury: Diagnostic approaches and controversies. Clin Biochem Rev. 2016;37(4):153-75.
[23]. KDIGO Acute Kidney Injury Work Group. KDIGO clinical practice guideline for acute kidney injury. Kidney Int Suppl. 2012;2(1):1-138.
[24]. Levin A, Tonelli M, Bonventre J, Coresh J, Donner JA, Fogo AB, et al. Global kidney health 2017 and beyond: a roadmap for closing gaps in care, research, and policy. Lancet. 2017;390(10105):1888-917.
[25]. Webster AC, Nagler EV, Morton RL, Masson P. Chronic kidney disease. Lancet. 2017;389(10075):1238-52.
[26]. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345(12):861-9.
[27]. Jha V, Garcia-Garcia G, Iseki K, Li Z, Naicker S, Plattner B, et al. Chronic kidney disease: global dimension and perspectives. Lancet. 2013;382(9888):260-72.
[28]. Lameire N, Van Biesen W, Vanholder R. Acute renal failure. Lancet. 2005;365(9457):417-30.
[29]. Uchino S, Bellomo R, Kellum JA, et al. Hypovolemia and sepsis-related acute renal failure. Crit Care Med. 2007;35(5):1297-303.
[30]. Schrier RW, Wang W, Poole B, et al. Acute renal failure: definitions, diagnosis, pathogenesis, and therapy. J Clin Invest. 2004;114(1):5-14.
[31]. Kellum JA, Lameire N. Diagnosis, evaluation, and management of acute kidney injury: a KDIGO summary (Part 1). Crit Care. 2013;17(1):204.
[32]. Bonventre JV, Yang L. Cellular pathophysiology of ischemic acute kidney injury. J Clin Invest. 2011;121(11):4210-21.
[33]. Gill JR, Bellomo R. Hyperkalemia in acute kidney injury: incidence, morbidity, and management. Nephrol Dial Transplant. 2011;26(3):615-20.
[34]. Kraut JA, Madias NE. Disorders of fluid, electrolyte, and acid-base balance in patients with chronic kidney disease. Clin J Am Soc Nephrol. 2008;3(3):641-52.
[35]. Perazella MA. Drug-induced acute kidney injury: diverse mechanisms of tubular injury. Curr Opin Crit Care. 2019;25(6):550-7.
[36]. Kraut JA, Madias NE. Metabolic acidosis of CKD: an update. Am J Kidney Dis. 2016;67(2):307-17.
[37]. Mehta RL, Pascual MT, Soroko S, et al. Spectrum of acute renal failure in the intensive care unit: the PICARD experience. Kidney Int. 2004;66(4):1613-21.
[38]. Vanholder R, Glorieux G, Lameire N. Uremic toxins in chronic kidney disease: review of pathophysiologic mechanisms. Toxins (Basel). 2018;10(7):287.
[39]. Chawla LS, Eggers PW, Star RA, et al. Acute kidney injury and chronic kidney disease as interconnected syndromes. N Engl J Med. 2014;371(1):58-66.
[40]. Levy MM, Artigas A, Phillips GS, et al. Outcomes of acute kidney injury patients in international sepsis trials. Crit Care Med. 2011;39(12):2665-71.
[41]. Gandhi R, Ku E. Postrenal acute kidney injury. In: Floege J, Johnson RJ, Feehally J, editors. Comprehensive clinical nephrology. 6th ed. Philadelphia: Elsevier; 2019. p. 850- 60.
[42]. Levey AS, Coresh J. Chronic kidney disease. Lancet. 2012;379(9811):165-80.
[43]. Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345(12):861-9.
[44]. Ritz E, Orth SR. Nephropathy in patients with type 2 diabetes mellitus. N Engl J Med. 1999;341(15):1127-33.
[45]. Levin A, Stevens PE, Bilous RW, et al. Kidney disease: improving global outcomes (KDIGO) CKD work group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl. 2013;3(1):1-150.
[46]. Agarwal R. Resistant hypertension and the role of aldosterone: an overview. Cardiol Clin. 2019;37(3):275-85.

IJARSCT
ISSN (Online) 2581-9429
International Journal of Advanced Research in Science, Communication and Technology (IJARSCT)
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
Impact Factor: 7.53
Volume 4, Issue 5, November 2024

[47]. Harris PC, Torres VE. Polycystic kidney disease. Annu Rev Med. 200
[48]. Kraut JA, Madias NE. Metabolic acidosis of CKD: an update. Am J Kidney Dis. 2016;67(2):307-17.
[49]. Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345(12):861-9.
[50]. Ritz E, Orth SR. Nephropathy in patients with type 2 diabetes mellitus. N Engl J Med. 1999;341(15):1127-33.
[51]. Levin A, Stevens PE, Bilous RW, et al. Kidney disease: improving global outcomes (KDIGO) CKD work group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl. 2013;3(1):1-150.
[52]. Harris PC, Torres VE. Polycystic kidney disease. Annu Rev Med. 2009;60:321-37.
[53]. Vanholder R, Glorieux G, Lameire N. Uremic toxins in chronic kidney disease: review of pathophysiologic mechanisms. Toxins (Basel). 2018;10(7):287.
[54]. Vanholder R, Van Biesen W, Lameire N. Chronic kidney disease as cause of cardiovascular morbidity and mortality. Nephrol Dial Transplant. 2008;23(1):16-20.
[55]. Go AS, Chertow GM, Fan D, et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004;351(13):1296-305.
[56]. Moe S, Drüeke T, Cunningham J, et al. Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 2006;69(11):1945-53.
[57]. Levin A, Bakris GL, Molitch M, et al. Prevalence of abnormal calcium-phosphate metabolism in patients with chronic kidney disease. Am J Kidney Dis. 2007;49(5):674- 82.
[58]. Palmer BF, Clegg DJ. Sexual dysfunction in chronic kidney disease: pathophysiology, evaluation, and treatment. Adv Chronic Kidney Dis. 2021;28(5):390-400.
[59]. Moledina DG, Parikh CR. Assessing the outcomes of acute kidney injury. Nat Rev Nephrol. 2017;13(4):241-257.
[60]. Levin A, Stevens PE, Bilous RW, et al. Kidney disease: Improving global outcomes (KDIGO) CKD guideline update. Kidney Int Suppl. 2013;3(1):1-150.
[61]. Kellum JA, Lameire N. Diagnosis, evaluation, and management of acute kidney injury: A KDIGO summary. Crit Care. 2013;17(1):204.
[62]. National Institute for Health and Care Excellence (NICE). Chronic kidney disease in adults: Assessment and management. NICE guideline (NG203). 2021.
[63]. Strippoli GFM, Craig JC, Schena FP, et al. Role of protein restriction in preventing progressive chronic kidney disease: Meta-analysis of randomised controlled trials. BMJ. 2002;324(7353):871-875.
[64]. Lameire N, Kellum JA, KDIGO AKI Guideline Work Group. Acute kidney injury: Diagnostic approach and initial management. Kidney Int Suppl. 2012;2(1):1-138.
[65]. Palevsky PM, Liu KD, Brophy PD, et al. KDOQI US commentary on the 2012 KDIGO clinical practice guideline for acute kidney injury. Am J Kidney Dis. 2013;61(5):649-672.
[66]. Bagshaw SM, Uchino S, Kellum JA, et al. Endotoxemia in septic acute kidney injury. J Crit Care. 2014;29(2):260-264
[67]. Legrand M, Mookerjee RP, Ronco C. Intrinsic acute kidney injury: Diagnosis and management. Clin J Am Soc Nephrol. 2017;12(12):224-236.
[68]. Srisawat N, Kellum JA. Acute kidney injury: Definition, epidemiology, and outcome. Curr Opin Crit Care. 2011;17(6):548-555.
[69]. Bhargava A, Rockman H. Acute glomerulonephritis: Immunosuppressive treatment approaches. Nat Rev Nephrol. 2013;9(5):297-309.
[70]. Fischer RG, Lachmann HJ, Weening JJ. Drug-induced acute interstitial nephritis: Pathogenesis and treatment. Nat Rev Nephrol. 2011;7(8):444-448.
[71]. Hsu CY, McCulloch CE, Fan D, et al. Noninvasive diagnosis and management of postrenal acute kidney injury. Am J Kidney Dis. 2014;64(4):569-578.

IJARSCT
ISSN (Online) 2581-9429
International Journal of Advanced Research in Science, Communication and Technology (IJARSCT)
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
Impact Factor: 7.53
Volume 4, Issue 5, November 2024

[72]. Bellomo R, Kellum JA, Ronco C. Acute kidney injury. Lancet. 2012;380(9843):756- 766.
[73]. Wang HE, Muntner P, Chertow GM, et al. Acute kidney injury and mortality in hospitalized patients. Am J Nephrol. 2012;35(4):349-355.
[74]. Lumlertgul N, Peerapornratana S, Srisawat N, et al. Fluid management and diuretics in AKI. Crit Care. 2019;23(1):306.
[75]. Daugirdas JT, Blake PG, Ing TS. Electrolyte and acid-base management in acute kidney injury. In: Handbook of Dialysis. 5th ed. Philadelphia: Lippincott Williams & Wilkins; 2014.
[76]. Morooka H, Teragawa H, Tomiyama Y, et al. Clinical practice guideline for hyperkalemia management in chronic kidney disease. Kidney Int Suppl. 2020;10(1):2-7.
[77]. Kitchlu A, Adhikari NK, Burns KE, et al. Treatment options for renal replacement therapy in acute kidney injury. Crit Care. 2015;19(1):146.
[78]. Tolwani AJ. Continuous renal replacement therapy: Principles and practice. Hemodial Int. 2019;23(S1)
[79]. Inker LA, Perrone RD, Robinson BM, et al. Management of chronic kidney disease. JAMA. 2021;326(2):185-196.
[80]. Cheung AK, Rahman M, Reboussin DM, et al. Blood pressure in chronic kidney disease. JAMA. 2022;327(2):199-210.
[81]. Upadhyay A, Earley A, Haynes SM, et al. Systematic review: Blood pressure target for chronic kidney disease and proteinuria as an effect modifier. Ann Intern Med. 2011;154(8):541-548.
[82]. Weir MR, Rolnick S, Christofides EA, et al. Calcium channel blockers in chronic kidney disease: A review of efficacy and safety. Am J Nephrol. 2011;34(6):464-475.
[83]. de Boer IH, Caramori ML, Chan JCN, et al. Diabetes and CKD: 2022 KDIGO clinical practice guideline update for diabetes management in chronic kidney disease. Kidney Int. 2022;102(5):980-999.
[84]. Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117-2128.
[85]. Mann JFE, Ørsted DD, Brown-Frandsen K, et al. Liraglutide and renal outcomes in type 2 diabetes. N Engl J Med. 2017;377(9):839-848.
[86]. Lewis EJ, Hunsicker LG, Clarke WR, et al. Proteinuria and treatment of chronic kidney disease: Reducing proteinuria with ACEIs and ARBs. N Engl J Med. 2001;345(12):851- 860.
[87]. Baigent C, Landray MJ, Reith C, et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease: A randomized controlled trial. Lancet. 2011;377(9784):2181-2192.
[88]. Palmer SC, Craig JC, Navaneethan SD, et al. Benefits and harms of statins in chronic kidney disease: Systematic review and meta-analysis. BMJ. 2012;344
[89]. Locatelli F, Del Vecchio L. Anemia management in chronic kidney disease. Nephrol Dial Transplant. 2013;28(7):1568-1574.
[90]. Pfeffer MA, Burdmann EA, Chen CY, et al. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med. 2009;361(21):2019-2032.
[91]. Cunningham J, Sprague SM, Cannata-Andía JB, et al. Management of mineral and bone disorder in chronic kidney disease: An update. J Nephrol. 2021;34(4):943-966.
[92]. KDIGO. Clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of CKD-MBD. Kidney Int Suppl. 2017;7(1):1-59.
[93]. Liu W, Zhang J, Wang H, et al. Effect of calcimimetics in patients with secondary hyperparathyroidism. Clin J Am Soc Nephrol. 2021;16(3):344-352.
[94]. Bansal VK, Nair PS, Bhardwaj G. Treatment of hyperkalemia in chronic kidney disease patients. Indian J Crit Care Med. 2021;25(1):61-66.
[95]. Kraut JA, Madias NE. Treatment of acute and chronic metabolic acidosis. Kidney Int. 2010;78(7):698-706.
[96]. Menon V, Kopple JD, Wang X, et al. Effect of a very low-protein diet on outcomes: The Modification of Diet in Renal Disease (MDRD) study. Am J Kidney Dis. 2009;53(2):208-219.

IJARSCT
ISSN (Online) 2581-9429
International Journal of Advanced Research in Science, Communication and Technology (IJARSCT)
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
Impact Factor: 7.53
Volume 4, Issue 5, November 2024

[97]. McMahon EJ, Bauer JD, Hawley CM, et al. Dietary sodium restriction in chronic kidney disease: A review. J Ren Nutr. 2012;22(5):367-374.

[98]. Shaman AM, Kowalski SR. Hyperkalemia in CKD: Review of pathophysiology, risk factors, and treatments. Adv Chronic Kidney Dis. 2021;28(1):72-79.

[99]. Wang AY, Lam CW, Chan IH, et al. Fluid overload in CKD: Pathophysiology, risk factors, and management. Kidney Int. 2019;96(1):68-78.

[100]. Orth SR, Ritz E. The beneficial effects of stopping smoking in chronic kidney disease. Nephrol Dial Transplant. 2012;27(5):1801-1802.

[101]. Johansen KL, Chertow GM, Kutner NG, et al. Low level of self-reported physical activity in ambulatory patients new to dialysis. Kidney Int. 2010;78(11):1164-1170.

[102]. Kumar VA, Craig JC, Wyld ML, et al. Hemodialysis versus peritoneal dialysis: Survival comparison of matched cohorts from the Australian and New Zealand dialysis and transplant registry. Am J Kidney Dis. 2017;70(2):248-257.

[103]. Mehrotra R, Devuyst O, Davies SJ, Johnson DW. The current state of peritoneal dialysis. J Am Soc Nephrol. 2016;27(11):3238-3252.

[104]. Hart A, Smith JM, Skeans MA, et al. OPTN/SRTR 2020 annual data report: Kidney. Am J Transplant. 2022;22(S2):21-136.

[105]. Morton RL, Tong A, Webster AC, et al. Patient information about the risks and benefits of medications: The views of patients with chronic kidney disease. Nephrology (Carlton). 2010;15(5):464-470.

[106]. Palmer SC, Vecchio M, Craig JC, et al. Prevalence of depression in chronic kidney disease: Systematic review and meta-analysis of observational studies. Kidney Int. 2013;84(1):179-191.